Department of Health and Social Care

There is no national policy specifically focused on implementing Peer Supported Open Dialogue.

The National Health Service follows evidence when implementing any approach at scale and will respond to any future changes in National Institute for Health and Care Excellence guidance. A research trial evaluating the impact of open dialogue in the NHS is due to report soon, at the following link:

https://www.ucl.ac.uk/brain-sciences/pals/research/clinical-educational-and-health-psychology/research-groups/oddessi/oddessi-trial

Nationally, we are committed to working with local NHS mental health providers to develop a new approach for mental health in 2026, including through the upcoming modern service framework for severe mental illness.

The Department is also supporting the development of the evidence base on mental health care through research and evaluation, including studies funded by the National Institute for Health and Care Research, to inform future decisions on effective models of care.

NHS England does not have a target date for digital prescription availability in all National Health Service hospitals. The NHS Digital Maturity Assessment 2025 showed that 93% of NHS hospital trusts have gone live with an electronic prescribing and medicines administration system. The 2026 Digital Maturity Assessment will provide the latest data later this year.

The Government is clear that artificial intelligence (AI) based mental health tools are intended to support and complement, not replace, National Health Service mental health services.

Within NHS mental health services, AI based tools are expected to play a supporting role, for example by helping with administrative tasks such as appointment management, triage support, and updating clinical records, enabling clinicians to spend more time delivering direct, person‑centred care. AI may also support evidence‑based digital interventions, such as digitally enabled therapies, where these are clinically appropriate and have been properly evaluated.

The Government is clear that AI based tools must not replace access to trained mental health professionals, particularly for people experiencing acute distress. Publicly available AI applications that are not deployed by the NHS, such as ChatGPT or Google Gemini, are not regulated as medical technologies and may offer incorrect or harmful information, and people experiencing mental health difficulties are strongly encouraged to seek support from qualified professionals through NHS services or trusted charities.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Government is clear that artificial intelligence (AI) based tools must not replace access to human‑delivered psychological support where this is clinically appropriate.

Digital and AI tools can be used to support mental health services and those in need of those services, for example by helping with administrative tasks, triage, or appointment management, and these benefits can enable clinicians to spend more time delivering direct care. However, decisions about treatment and care must always be clinically led and based on individual patient need.

Publicly available AI applications that are not deployed by the National Health Service, such as ChatGPT or Google Gemini, are not regulated as medical technologies and may offer incorrect or harmful information. People experiencing mental health difficulties are strongly encouraged to seek support from qualified professionals through NHS services or trusted charities.

Spending across mental health services, both specialised commissioning and ICB combined, and including learning disability, autism, and dementia, is planned to increase to £20.616 billion in 2025/26, compared to £18.988 billion in 2024/25. Specific funding has also been allocated to expand mental health support in schools to 100% of institutions by 2029/30.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Medicines and Healthcare products Regulatory Agency (MHRA) supports access to treatments for people living with neuromuscular diseases. The majority of neuromuscular diseases are defined as rare diseases. On the 2 November 2025, the MHRA published a policy paper on rare therapies and United Kingdom regulatory considerations, which is available at the following link:

https://www.gov.uk/government/publications/rare-therapies-and-uk-regulatory-considerations/rare-therapies-and-uk-regulatory-considerations

The Early Access to Medicines Scheme (EAMS), is an existing pathway across the regulatory and access system designed to support innovative treatments being available to patients earlier in the development cycle, outside of a clinical trial. This includes for those living with neuromuscular diseases. The Government is collaborating across the regulatory system to continuously review the effectiveness of these pathways for rare diseases. Further information on the EAMS is available at the following link:

https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

While the Personal Child Health Record (PCHR) does not currently contain a dedicated section on diabetes, it includes signposting to National Health Service online information on serious childhood illness, including symptoms of diabetes.

NHS England is working with clinical experts, royal colleges, and wider stakeholders to review whether further opportunities exist to improve awareness of the key signs and symptoms of type 1 diabetes among both healthcare professionals and the public. This includes, as I set out in the Westminster Hall debate on this issue last week, looking carefully to see what further improvements might be made to the red book.

The Department for Environment Food and Rural Affairs and the Food Standards Agency (FSA) assess the level of food insecurity in the population. The FSA refers to the 1996 World Food Summit definition that “Food security exists when all people, at all times, have physical and economic access to sufficient, safe and nutritious food that meets their dietary needs and food preferences for an active and healthy life”.

The relationship between food insecurity, nutritional intake, and health in the UK is currently unclear. However, international evidence suggests that in the long-term, food insecurity may be associated with poorer diets and poorer health, including higher risk of overweight and obesity.

The Scientific Advisory Committee on Nutrition (SACN) provides independent scientific advice and risk assessments on nutrition and related health issues. The SACN’s remit includes matters concerning nutrient content of individual foods, advice on diet, and the nutritional status of the UK population. The SACN undertakes robust risk assessments and provides dietary recommendations.

The Government’s food strategy for England aims to achieve more affordable, accessible and healthier food for everyone, particularly for those on low incomes. We will set out more detail as the work progresses.

The Government is committed to improving the lives of people living with rare diseases through the UK Rare Diseases Framework. One of the priorities of the framework is improving awareness of all rare diseases, including Achalasia, among healthcare professionals. In England, we published the fifth action plan updating on the progress of this priority of the UK Rare Diseases Framework on 27 February 2026.

The NHS National Genomics Education Programme provides information to health care professionals through the online resource GeNotes. Since launching in 2022, GeNotes has expanded to 12 specialties, and more than 150 rare diseases. New diseases continue to be added.

Information for families on Achalasia is available on the National Health Service website, at the following link:

https://www.nhs.uk/conditions/achalasia/

The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours, such as glioblastoma, and recognises the significant impact that this rare cancer can have on patients, carers, and their families.

In October 2025, a new nationwide trial was launched exploring whether surgery can improve the quality of life for patients when glioblastoma comes back after treatment commenced, backed by £1.98 million of National Institute of Health and Care Research (NIHR) funding.

The Government published the National Cancer Plan for England on 4 February 2026, and it was the first ever cancer plan to include a chapter on rare and less common cancers. The plan sets out that we will aim to reduce the number of cancers diagnosed in emergency settings.

To accelerate breakthroughs, the Government will explore innovative procurement methods, such as advance market commitments, to stimulate the development of new diagnostic tests, targeted therapies and more effective treatments for rare cancers, such as brain cancers.

As a result of the significant new commitments to brain tumour research being announced, committed spend on brain tumour research from NIHR programmes alone is now in excess of £40 million since 2018. This is in addition to NIHR investments in infrastructure, which are estimated to be £44.5 million over the period 2018/19 to 2024/25, and UK Research and Innovation commitments of £46.8 million to brain tumour research over the six years from 2018/19 to 2023/24.

As I reaffirmed in the Westminster Hall debate on type 1 diabetes on 9 March 2026, the Government is committed to improving awareness of type 1 diabetes. NHS England carried out communications activity to coincide with World Diabetes Day in November 2025, with a focus on the “4Ts” symptoms of type 1 diabetes, namely thirst, tired, thinning, and toileting, meaning increased urine output. This included messaging to the public via social media, and the cascade of information via clinical networks.

NHS England is currently engaging and coordinating with other national organisations on supportive action, raising awareness of the symptoms of type 1 diabetes, improving training and education, and exploring what supportive tools may be available to further support healthcare professionals to identify type 1 diabetes.

Standard operating procedures (SOPs) for the fresh-freezing of tissue examples have already been developed across pathology networks in England. It is, however, the responsibility of individual pathology services to maintain their own SOPs for the fresh-freezing of tissue samples. These protocols outline local capabilities and practices.

There are no current plans to introduce one standardised approach for the fresh-freezing of tissue samples. NHS England is committed to addressing variation in the provision of pathology services, particularly histopathology, of which the investigation of brain and neural tissues is a core element.

The Department is exploring options to expand brain tissue freezing capacity.

Standard operating procedures (SOPs) for the fresh-freezing of tissue examples have already been developed across pathology networks in England. It is, however, the responsibility of individual pathology services to maintain their own SOPs for the fresh-freezing of tissue samples. These protocols outline local capabilities and practices.

There are no current plans to introduce one standardised approach for the fresh-freezing of tissue samples. NHS England is committed to addressing variation in the provision of pathology services, particularly histopathology, of which the investigation of brain and neural tissues is a core element.

The Department is exploring options to expand brain tissue freezing capacity.

Standard operating procedures (SOPs) for the fresh-freezing of tissue examples have already been developed across pathology networks in England. It is, however, the responsibility of individual pathology services to maintain their own SOPs for the fresh-freezing of tissue samples. These protocols outline local capabilities and practices.

There are no current plans to introduce one standardised approach for the fresh-freezing of tissue samples. NHS England is committed to addressing variation in the provision of pathology services, particularly histopathology, of which the investigation of brain and neural tissues is a core element.

The Department is exploring options to expand brain tissue freezing capacity.

The Department and the National Health Service in England acknowledge that some cancer patients may face difficulties with hair loss during treatment.

Decisions about the funding and provision of health services are the responsibility of local integrated care boards. NHS Supply Chain has engaged extensively on a national level to thoroughly assess the provision and supply of wigs and related accessories. Collaboration between NHS Supply Chain with industry groups is ongoing to facilitate access to the wigs framework, thereby offering NHS providers a broader selection of products. A key priority throughout this process has been ensuring suitability for individual wearers.

The Government is committed to ensuring that anyone with an alcohol problem can access the help and support they need, including in South Basildon and East Thurrock, and we recognise the need for evidence-based, high-quality treatment.

Local authorities are responsible for commissioning alcohol and drug treatment and recovery services as part of their public health responsibilities. As a condition of the Public Health Grant, local authorities are responsible for improving the uptake of, and outcomes from, their alcohol and drug treatment services, based on an assessment of local need and a plan which has been developed with local health and criminal justice partners. From 2026/27, all alcohol and drug treatment and recovery funding will be ringfenced and channelled through the Public Health Grant. Through the ringfenced funding, Essex will receive £11,023,044 in 2026/27 and indicative totals of £11,247,572 and £11,466,588 for 2027/28 and 2028/29 respectively. Thurrock will receive £1,588,644 in 2026/27 and indicative totals of £1,621,003 and £1,652,567 for 2027/28 and 2028/29 respectively.

The Department, with the support of partners from the devolved administrations, has developed and published the first ever United Kingdom clinical guidelines on alcohol treatment. This is available at the following link:

https://www.gov.uk/guidance/clinical-guidelines-for-alcohol-treatment

The aim of the guidelines is to promote and support good practice and improve the quality of service provision, resulting in better outcomes for people experiencing harmful drinking and alcohol dependence.

The Department recognises the significant impact that chronic pain has on individuals and the importance of ensuring that National Health Service‑funded pain management services are effective, accessible and evidence‑based. Integrated care boards (ICBs) commission a range of multidisciplinary pain management programmes across primary, community, and specialist care to help people manage persistent pain. These services include pharmacological and non‑pharmacological interventions, such as physiotherapy, psychological therapies, and supported self‑management.

When commissioning pain management services, ICBs should have regard to the chronic pain guideline published by the National Institute for Health and Care Excellence (NICE), reference code NG193, as NICE’s evidence‑based recommendations set out nationally recognised best practice for assessing and treating chronic pain, helping to ensure that commissioned services are safe, effective, and aligned with the highest clinical standards.

The Getting It Right First Time Chronic Pain workstream, introduced in 2025, is reviewing pain services across all care settings to identify unwarranted variation and improve access, equity, and outcomes for people living with chronic pain. This work is aligned with wider NHS and Government plans to promote integrated, proactive, and person‑centred long‑term condition management.

Through the 10‑Year Health Plan, the Government is expanding community‑based services, strengthening multidisciplinary care models, and improving access to diagnostics and specialist input, all of which support better management of long‑term conditions such as chronic pain. These measures will contribute to improving the adequacy and consistency of NHS‑funded pain management services across England.

There is currently no national prostate cancer screening programme. The UK National Screening Committee (UK NSC) is an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and supports implementation. They recently closed a consultation on their draft recommendation to:

• offer a targeted national prostate cancer screening programme to men with confirmed BRCA1/2 gene variants every two years, from 45 years old to 61 years old;
• not recommend population screening;
• not recommend targeted screening of black men;
• not recommend targeted screening of men with family history; and
• collaborate with the Transform trial team to answer outstanding questions on screening effectiveness for black men and men with a family history as soon as the trial data becomes available, and to await the results of the study to develop and trial a more accurate test than the prostate specific antigen test alone, to improve the balance of benefit and harm of screening.

The evidence that supports this draft recommendation can be found on the UK NSC prostate cancer recommendation page, at the following link:

https://nationalscreening.blog.gov.uk/2025/11/28/uk-nsc-opens-consultation-on-draft-prostate-cancer-screening-recommendation/

In Fit for the Future: 10-Year Health Plan for England, the Government has committed to explore measures to regulate access to no- and low-alcohol (NoLo) products in line with other alcoholic beverages. This policy is being pursued as alcohol substitute drinks are only intended for consumption by adults.

Department officials are progressing work to take forward this commitment and are in the process of scoping out the full details. We will update stakeholders in due course.

There are no current plans to change the licensing rules in pubs for 16- and 17-year-olds.

NHS England will be developing a national commissioning specification during the first half of 2026/27 to ensure consistent, high-quality care across all gambling treatment and support services nationwide. Given the evolving evidence landscape and NHS England’s plans to allocate funding to innovation and evaluation over the coming years, this document will be updated as required to reflect new findings.

Alongside our Tobacco and Vapes Bill, we remain committed to supporting current smokers to quit.

The Government has invested an additional £70 million in both 2024/25 and 2025/26 to support local authority-led Stop Smoking Services in England to help people quit. We are already seeing the impact this has made, with the first year of additional funding in 2024/25 having resulted in a 23% increase in the number of people supported to quit compared to the previous year.

From April 2026, we will ring-fence all funding for smoking cessation services within the Public Health Grant, meaning at least £153 million, increasing to £155 million in 2028/29, will be protected for these services. The additional funding will ensure there is a comprehensive offer across local authorities in England, with funding weighted toward local authorities with the highest smoking rates. The Better Health Website is also available and contains comprehensive cessation advice to support individuals to find the right approach for them.

In addition, the 10-Year Health Plan for England restated our commitment to integrate opt-out smoking cessation interventions into routine care within all hospitals. As of Quarter 3 of 2025/26, 99% of eligible maternity services and 92% of eligible in-patient services had an opt-out tobacco dependence treatment offer.

As health is a devolved matter, local stop smoking support in Scotland and Wales is the responsibility of the devolved administrations.

Subject to final checks, this year the statutory levy has raised just under £120 million, which will be ringfenced solely for the use of tackling gambling-related harm. In England, prevention and treatment funding will include: £15.9 million for integrated care boards in 2026/27 to commission regional National Health Service gambling services; up to £20 million through NHS England’s Gambling Harms Treatment Voluntary, Community, and Social Enterprise (VCSE) Grant Scheme to ensure that those affected by gambling-related harms can continue to access VCSE sector treatment and support services during 2026/7; up to £30 million through the Office for Health Improvement and Disparities’ VCSE Gambling Harms Prevention Fund for 2026 to 2028; a two‑year prevention grant for all upper tier local authorities for 2026 to 2028; and additional funding during 2026/27 for service delivery and programme activities, such as evaluation and workforce development. Details on awarded funding will be published in due course.

Gloucestershire has a county wide programme in place to improve diabetes care and increase uptake of these checks. Current actions include:

• a primary care Locally Enhanced Service for diabetes and diabetes champions, to support earlier intervention, more consistent reviews, and better diabetes management in general practices;
• a local diabetes performance dashboard that gives practices real time data to identify variation and target support;
• a community diabetes consultant, supporting increased access to specialist advice in community settings so people are able to access care closer to home and reducing pressure on hospital services; and
• active involvement in NHS England’s regional diabetes oversight work to share learning and benchmark performance.

These steps aim to support earlier diagnosis, more consistent monitoring, and better outcomes for people living with diabetes in Gloucester and across the county.

The latest data from the quarterly National Diabetes Audit for 2025/26 indicates Gloucestershire’s steady improvement in both the delivery of key checks and the achievement of the recommended treatment targets for people with both Type 1 and Type 2 diabetes.

NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease, through its renal services transformation programme. This includes a specification for renal services which sets out the scope for the work of the renal clinical networks commissioned across England. The specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/05/PRN231110-renal-clinical-network-specification-2023-.pdf

The goals of the specification include reducing variation across the renal care pathway by developing, agreeing and implementing standardised pathways of care, including dialysis and home therapy services for adult and paediatric services. The eight regional kidney networks in England, working with providers, will review service delivery across network against need and identify gaps and variation in services, gaps in overall provision, quality, geographical distribution, and deliver improvements to network services to address these issues.

On 28 November 2025, the UK National Screening Committee (UK NSC) opened a 12-week public consultation on a draft recommendation to offer targeted screening for prostate cancer in men with variants of BRCA1 and BRCA2 genes, every two years from the age of 45 to 61 years old. This consultation has now closed, and the committee is considering the responses.

We welcome the UK NSC’s consideration of the evidence and robust consultation process. We expect the UK NSC to make a final recommendation soon. My Rt Hon. Friend, the Secretary of State for Health and Social Care, will then consider the advice, make a decision, and determine the next steps.

Each action in the final delivery plan on myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), has a designated lead department or organisation, with the Department of Health and Social Care being ultimately responsible for overseeing the delivery of the plan as a whole, including holding other organisations to account for delivering actions.

At this stage, Department and NHS England officials have been working carefully through the steps needed to make a decision on the prescription of a specialised service for very severe ME/CFS. My Rt Hon. Friend, the Secretary of State for Health and Social Care, is responsible for a decision on the prescribing of specialised services, which requires consultation with NHS England.

The Department is currently developing a template service specification for mild and moderate myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), which also references severe ME/CFS. Further work will need to be undertaken to strengthen support for people with severe ME/CFS, reflecting that people may move between moderate and severe. Future iterations of this document will build on ongoing considerations and emerging insights of severe and very severe ME/CFS.

Departmental and NHS England officials have been working carefully through the steps needed to make a decision on the prescription of a specialised service for very severe ME/CFS. My Rt Hon. Friend, the Secretary of State for Health and Social Care, is responsible for a decision on the prescribing of specialised services, which requires consultation with NHS England.

To support healthcare professionals in the diagnosis and management of ME/CFS, the Department has worked with NHS England to develop an e-learning programme on ME/CFS for healthcare professionals. The final module of this e-learning programme is focussed on managing severe ME/CFS.

Additionally, as set out in the Plan for Change, we are committed to returning to the National Health Service constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment by March 2029. We delivered 5.2 million additional appointments between July 2024 and June 2025. This will help people with severe ME/CFS to get support sooner. The Plan for Change is available at the following link:

https://www.gov.uk/missions

The 10-Year Health Plan sets out a transformed vision for elective care by 2035, where most interactions no longer take place in a hospital building, instead happening virtually or via neighbourhood services. This will enable patients with severe or very severe ME/CFS who are housebound or bedbound to access support more easily.

The NHS Cancer Vaccine Launch Pad (CVLP) is a platform set up to accelerate the development of cancer vaccines and speed up access to mRNA personalised cancer vaccine clinical trials for cancer patients. The CVLP has been instrumental in accelerating trial activity in cancer research, with CVLP sites driving faster activation and enrolment timelines.

The CVLP provides an extended network of referral sites to broaden trial access and to identify eligible patients through genetic analysis, working with the Vaccine Innovation Pathway to optimise patient recruitment. This means that patients can be recruited from across parts of the country and means that the United Kingdom was the fastest recruiting country for the first international trial of personalised vaccination after surgery for colorectal cancer.

As the CVLP continues its phased scale-up across the country, professional awareness is being driven by the expansion of participating trial sites and use of the referral network.

The Department of Health and Social Care and the Department for Education are working jointly to produce and publish new advice for parents and carers on the impacts of screen use on the health and development of children aged zero to five years old, including speech and language development. An expert group of child health and development specialists has been convened to review the evidence and produce a report for the Government. The Government’s advice for parents and carers will be informed by this report, our Call for Evidence, and direct engagement with parents and carers. The advice will be published by 1 April 2026.

There is an emerging evidence base focusing on device use amongst children. However, many factors influence children’s development and there is limited evidence on the causal relationship between screen use and children’s health and development. We continue to learn from ongoing studies collecting data about young children, including the Department for Education’s Children of the 2020s longitudinal study, with further information available at the following link:

https://children2020s.ipsos.com/

This study found that higher screentime at two years old was independently associated with lower vocabulary development, and higher emotional and behaviour problems. However, other important factors such as economic circumstances and the child’s wider home learning environment also impact these outcomes and may influence why a family uses devices more.

The Department of Health and Social Care works with the Ministry of Housing, Communities and Local Government on the links between housing conditions and health, including the risks associated with damp, mould, and other hazards. The jointly published guidance Understanding and addressing the health risks of damp and mould in the home sets out the health risks of damp and mould and the steps landlords should take to address these issues. This guidance is avaiable at the following link:

https://www.gov.uk/government/publications/damp-and-mould-understanding-and-addressing-the-health-risks-for-rented-housing-providers/understanding-and-addressing-the-health-risks-of-damp-and-mould-in-the-home--2

The Decent Homes Standard (DHS) is part of the package of Government action and investment to support improvements in the quality of rented homes, including implementation of Awaab’s Law, the Renters’ Rights Act, and minimum energy efficiency standards. One aim of these measures is to reduce illness linked to damp, mould, and other housing hazards.

The new DHS prioritises safety, decency, and warmth. The Department of Health and Social Care’s engagement has focused on the health-related aspects of the DHS. Decisions on the implementation timetable have been led by the Ministry of Housing, Communities and Local Government, and informed by consultation with the sector. The Government expects landlords to begin taking action now to ensure their properties meet the DHS. We recognise, however, that it will take time to plan and deliver works sustainably. The Department of Health and Social Care will work with the Ministry of Housing, Communities and Local Government to produce guidance to support implementation of the DHS. The DHS is avaiable at the following link:

https://www.gov.uk/government/consultations/consultation-on-a-reformed-decent-homes-standard-for-social-and-privately-rented-homes